🇺🇸 FDA
Patent

US 11287427

Application of anti-CD39L3 antibodies for use in disease diagnostics and imaging

granted A61KA61K35/39A61P

Quick answer

US patent 11287427 (Application of anti-CD39L3 antibodies for use in disease diagnostics and imaging) held by THE UNITED STATES AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS expires Mon Mar 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
THE UNITED STATES AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS
Grant date
Tue Mar 29 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
3
CPC classes
A61K, A61K35/39, A61P, A61P3/08